Daxor announces that the United States Patent and Trademark Office has issued the company a second patent, safeguarding a distinctive clinical guidance system for blood volume management. This system utilizes unique blood volume metrics and related clinical measures to create support guidance for fluid management interventions. “Given the cost and complexity of healthcare, intelligent computer-assisted support tools are a major focus for hospital systems to improve outcomes and reduce costs. At Daxor, our mission is to advance healthcare by enabling optimal fluid management, equipping physicians with the tools for more effective diagnosis and treatment. Our proprietary technology, protected by numerous patents, ensures a distinct advantage as we introduce next-generation products to the market, advancing this mission,” said Michael Feldschuh, Daxor’s CEO and President.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DXR:
- Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer
- Daxor submits dual 510k/CLIA-waiver application to FDA for Daxor BVA
- Daxor presents data from Phase 1 NIH sponsored RCT on BVA-100
- New Randomized Controlled Trial Demonstrates the Efficacy of Daxor’s BVA Guided-Care in Heart Failure Patients
- Daxor awarded new patent for remote monitoring of blood volume
